Abstract
Cystinuria is a genetic disorder of impaired renal and intestinal transport of cystine and dibasic amino acids. It often presents in childhood and is characterized by the recurrent formation of kidney stones throughout a patient’s lifetime. Patients with cystinuria have an increased risk of the development of chronic kidney disease, even in comparison to other types of stone formers. Due to the significant morbidity associated with both passing kidney stones and undergoing procedures to remove them, the prevention of stone formation is an important focus of treatment. Urinary parameters such as volume, pH, cystine concentration and capacity, and dietary protein and sodium content are all important targets of therapy. A combination of fluid therapy, dietary modifications, alkalinizing agents, and medications such as cystine-binding thiol drugs (tiopronin and d-penicillamine) are considered for each patient in order to attempt to lower the risk of forming cystine stones. We review what is known about the assessment of risk in patients with cystinuria and the management options that are available today or on the horizon.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Chillarón J, Font-Llitjós M, Fort J, Zorzano A, Goldfarb DS, Nunes V, et al. Pathophysiology and treatment of cystinuria. Nat Rev Nephrol. 2010 Jul;6:424–34.
Segal S, Thier SO. Cystinuria. In: Scriver CR, Beaudet AL, Sly WS, Valle D, Editors. The metabolic basis of inherited disease. 6th edn. New York: McGraw-Hill; 1989. pp. 2479–96.
Della Strologo L, Pras E, Pontisilli C, Beccia E, Ricci-Barbini V, de Sanctis L, et al. Comparison between SLC3A1 and SLC7A9 cystinuria patients and carriers—a need for a new classification system. J Am Soc Nephrol. 2002 Oct;13(10):2547–53.
Gucev Z, Ristoska-Bojkovska N, Popovska-Jankovic K, Sukarova-Stefanovska E, Tasic V, Plaseska-Karanfilska D, et al. Cystinuria AA (B): Digenic inheritance with three mutations in two cystinuria genes. J Genet. 2011 Apr; 90(1):157–9.
Nakagawa Y, Asplin JR, Goldfarb DS, Parks JH, Coe FL. Clinical use of cystine supersaturation measurements. J Urol. 2000 Nov;164(5):1481–5.
Birwé H, Hesse A. High-performance liquid chromatographic determination of urinary cysteine and cystine. Clin Chim Acta. 1991 May;199(1):33–42.
Coe FL, Clark C, Parks JH, Asplin JR. Solid phase assay of urine cystine supersaturation in the presence of cystine binding drugs. J Urol. 2001 Aug;166(2):688–93.
Rule AD, Krambeck AE, Lieske JC. Chronic kidney disease in kidney stone formers. Clin J Am Soc Nephrol. 2011 Aug;6(8):2069–75.
Worcester EM, Parks JM, Evan AP, Coe FL. Renal function in patients with nephrolithiasis. J Urol. 2006 Aug;176(2):600–3.
Assimos DG, Leslie SW, Ng C, Streem SB, Hart LJ. The impact of cystinuria on renal function. J Urol. 2002 Jul;168(1):27–30.
Milliner D, Goldfarb DS, Beara-Lasic L, Edvardsson V, Bergstralh E, Lieske JC, et al. E19 Kidney function in genetic stone formers. Eur Urol Suppl 2013;12(3):36.
Dent CE, Senior B. Studies on the treatment of cystinuria. Br J Urol. 1955 Dec;27(4):317–32.
Goldfarb DS, Coe FC, Asplin JR. Urinary cystine excretion and capacity in patients with cystinuria. Kidney Int. 2006 Mar;69(6):1041–7.
Rodman JS, Blackburn P, Williams JJ, Brown A, Pospischil MA, Peterson CM. The effect of dietary protein on cystine excretion in patients with cystinuria. Clin Nephrol. 1984 Dec;22(6):273–8.
Jaeger P, Portmann L, Saunders A, Rosenberg LE, Their SO. Anticysinuric effects of glutamine and dietary sodium restriction. N Engl J Med. 1986 Oct 30;315(18):1120–3.
Rodríguez LM, Santos F, Málaga S, Martínez V. Effect of a low sodium diet on urinary elimination of cystine in cystinuric children. Nephron. 1995;71(4):416–8.
Crawhall JC, Scowen EF, Watts RW. Effect of peniciallamine of cystinuria. Br Med J. 1963 Mar 2;1(5330):588–90.
McDonald WB, Fellers FX. Penicillamine in the treatment of patients with cystinuria. J Am Med Assoc. 1966;197(6):396–402.
Dahlberg PJ, van den Berg CJ, Kurtz SB, Wilson DM, Smith LH. Clinical features and management of cystinuria. Mayo Clin Proc. 1977 Sep;52(9):533–42.
Remien A, Kallistratos G, Burchardt P. Treatment of cystinuria with Thiola. Eur Urol. 1975;1(5):227–8.
Barbey F, Joly D, Rieu P, Méjean A, Daudon M, Jungers P. Medical treatment of cystinuria: Critical appraisal of long-term results. J Urol. 2000 May;163(5):1419–23.
Della Stologo L, Laurenzi C, Legato A, Pastore A. Cystinuria in children and young adults: success in measuring free-cystine urine levels. Pediatr Nephrol. 2007 Nov; 22(11):1869–73.
Jaffe IA. Adverse effects profile of sulhydryl compounds in man. Am J Med. 1986 Mar;80(3):471–6.
Munday R. Toxicity of thiol and disulfides: Involvement of free radical species. Free Radic Biol Med. 1989;7(6):659–73.
Pak CY, Fuller C, Sakhaee K, Zerwekh JE, Adams BV. Management of cystine nephrolithiasis with alpha-mercaptopropionylglycine. J Urol. 1986 Nov;136(5):1003–8.
Rimer JD, An Z, Zhu Z, Lee MH, Goldfarb DS, Wesson JA, Ward MD. Crystal growth inhibitors for the prevention of L-cystine kidney stones through molecular design. Science. 2010 Oct;330(6002):337–41.
Moran A., Ben-Nun A, Potashnik R, Bashan N. Renal cells in culture as a model for cystinosis. J Basic Clin Physiol Pharmacol. 1990 Jan–Dec;1(1–4):357–72.
Sahota A, Yang M, Shikhel S, et al. Tailored inhibition of cystine stone formation as a therapy for cystinuria. J Inherit Metab Dis. 2012;35(S1):S27.
Acknowledgments
We gratefully acknowledge the support of the Rare Kidney Stone Consortium (U54KD083908), a part of Rare Diseases Clinical Research Network (RDCRN), funded by the NIDDK and National Center For Advancing Translational Sciences (NCATS).
Disclosures
No external funding sources contributed to this study. Goldfarb is a consultant for Takeda, Keryx; a CME speaker for Quintiles, Mission; owner of Ravine Group; and has received funding from NIDDK, ORDR.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2014 Springer Science+Business Media New York
About this chapter
Cite this chapter
Sumorok, N., Goldfarb, D. (2014). Cystinuria: Assessing and Managing Risk. In: Pearle, M., Nakada, S. (eds) Practical Controversies in Medical Management of Stone Disease. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-9575-8_8
Download citation
DOI: https://doi.org/10.1007/978-1-4614-9575-8_8
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4614-9574-1
Online ISBN: 978-1-4614-9575-8
eBook Packages: MedicineMedicine (R0)